ABEONA THERAPEUTICS INC. (ABEO)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| License and other revenues | 400 | - | - | - |
| General and administrative | - | 9,786 | 6,404 | 8,646 |
| Selling, general and administrative | 17,149 | - | - | - |
| Royalties | 100 | - | - | - |
| Research and development | 5,943 | 9,941 | 8,941 | 9,218 |
| Total expenses | 23,192 | 19,727 | 15,345 | 17,864 |
| Loss from operations | -22,792 | -19,727 | -15,345 | -17,864 |
| Other income | 89 | 141 | 145 | 224 |
| Interest income | 1,027 | 1,310 | 1,189 | 1,191 |
| Interest expense | 957 | 998 | 1,102 | 1,072 |
| Change in fair value of warrant and derivative liabilities | 5,388 | -7,245 | 15,156 | -24,927 |
| Gain from sale of priority review voucher, net | 152,366 | - | - | - |
| Income (loss) before income taxes | 124,345 | - | - | - |
| Income tax expense | 15,512 | - | - | - |
| Net income (loss) | 108,833 | -12,029 | -30,269 | 7,406 |
| Change in unrealized gains related to available-for-sale debt securities | 22 | -75 | 50 | 50 |
| Comprehensive income (loss) | 108,855 | -12,104 | -30,219 | 7,456 |
| Basic | 52,524,510 | 49,778,801 | 48,081,758 | 40,010,481 |
| Basic income (loss) per common share | 2.07 | -0.24 | -0.63 | 0.19 |
| Dilutive | 66,640,620 | 49,778,801 | 48,081,758 | 51,226,715 |
| Dilutive income (loss) per common share | 1.71 | -0.24 | -0.63 | -0.26 |